116 related articles for article (PubMed ID: 29174535)
1. Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human.
Haraya K; Kato M; Chiba K; Sugiyama Y
Drug Metab Pharmacokinet; 2017 Dec; 32(6):277-285. PubMed ID: 29174535
[TBL] [Abstract][Full Text] [Related]
2. Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers.
Haraya K; Kato M; Chiba K; Sugiyama Y
Drug Metab Pharmacokinet; 2016 Aug; 31(4):276-84. PubMed ID: 27318879
[TBL] [Abstract][Full Text] [Related]
3. Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers.
Kadam R; Bourne D; Kompella U; Aquilante C
Biol Pharm Bull; 2013; 36(2):245-51. PubMed ID: 23370354
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone.
Itkonen MK; Tornio A; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
Drug Metab Dispos; 2016 Aug; 44(8):1364-71. PubMed ID: 27260150
[TBL] [Abstract][Full Text] [Related]
5. The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
Naik H; Wu JT; Palmer R; McLean L
Br J Clin Pharmacol; 2012 Aug; 74(2):327-35. PubMed ID: 22242967
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers.
Aquilante CL; Wempe MF; Spencer SH; Kosmiski LA; Predhomme JA; Sidhom MS
Pharmacotherapy; 2013 Sep; 33(9):1000-7. PubMed ID: 23712614
[TBL] [Abstract][Full Text] [Related]
7. Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals.
Yin SJ; Qi HM; Wang X; Zhang P; Lu Y; Wei MJ; Li P; Qi GZ; Lou YQ; Lu C; Zhang GL
Pharmacogenet Genomics; 2017 Apr; 27(4):125-134. PubMed ID: 28099407
[TBL] [Abstract][Full Text] [Related]
8. Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans.
Chiba K; Shimizu K; Kato M; Miyazaki T; Nishibayashi T; Terada K; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2695-2703. PubMed ID: 28435143
[TBL] [Abstract][Full Text] [Related]
9. Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
Backman JT; Filppula AM; Niemi M; Neuvonen PJ
Pharmacol Rev; 2016 Jan; 68(1):168-241. PubMed ID: 26721703
[TBL] [Abstract][Full Text] [Related]
10. Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
Doki K; Darwich AS; Achour B; Tornio A; Backman JT; Rostami-Hodjegan A
Br J Clin Pharmacol; 2018 May; 84(5):972-986. PubMed ID: 29381228
[TBL] [Abstract][Full Text] [Related]
11. Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans.
Chiba K; Shimizu K; Kato M; Nishibayashi T; Terada K; Izumo N; Sugiyama Y
Drug Metab Pharmacokinet; 2014; 29(5):379-86. PubMed ID: 24739523
[TBL] [Abstract][Full Text] [Related]
12. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.
Kosoglou T; Kumar B; Statkevich P; Schiller JE; Kantesaria B; Hanson ME; Sisk CM; Cutler DL
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):56-62. PubMed ID: 27128003
[TBL] [Abstract][Full Text] [Related]
13. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
Aquilante CL; Bushman LR; Knutsen SD; Burt LE; Rome LC; Kosmiski LA
Hum Genomics; 2008 Sep; 3(1):7-16. PubMed ID: 19129086
[TBL] [Abstract][Full Text] [Related]
14. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Niemi M; Neuvonen PJ
Eur J Clin Pharmacol; 2006 Jul; 62(7):503-9. PubMed ID: 16670899
[TBL] [Abstract][Full Text] [Related]
15. Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Surry D; Sweeny D; Lau D; Leese P
Clin Pharmacol Drug Dev; 2016 May; 5(3):170-9. PubMed ID: 27163495
[TBL] [Abstract][Full Text] [Related]
16. The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects.
Caltabiano S; Mahar KM; Lister K; Tenero D; Ravindranath R; Cizman B; Cobitz AR
Pharmacol Res Perspect; 2018 Apr; 6(2):e00327. PubMed ID: 29545948
[TBL] [Abstract][Full Text] [Related]
17. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects.
Kim KA; Park PW; Kim HK; Ha JM; Park JY
J Clin Pharmacol; 2005 Aug; 45(8):941-6. PubMed ID: 16027405
[TBL] [Abstract][Full Text] [Related]
18. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.
Kim KA; Park PW; Kim KR; Park JY
Br J Clin Pharmacol; 2007 Mar; 63(3):339-45. PubMed ID: 16981900
[TBL] [Abstract][Full Text] [Related]
19. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.
Pedersen RS; Damkier P; Brosen K
Br J Clin Pharmacol; 2006 Dec; 62(6):682-9. PubMed ID: 16856883
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
